Home Financial Markets Advaxis Inc (ADXS) stock has surged in the current trading session; here’s...

Advaxis Inc (ADXS) stock has surged in the current trading session; here’s why

In the current trading session, at last check, Advaxis Inc., ADXS stock had surged by 54.09% to trade at the price of $0.74. ADXS stock previously closed the session at $0.49. The ADXS stock volume traded at 33.69 million shares, which was higher than the average three-month volume of 6.50 million shares within the past 3 months. In the past year up to date, ADXS stock had shed -32.73% however in the past week the shares have moved up by 18.98%. In the past three and six months, the stock has lost -65.58% and added 21.33%. Furthermore, Advaxis Inc. is currently valued in the market at $62.08 million and has 137.96 million outstanding shares.

What you need to know about Advaxis Inc.

Advaxis, Inc.is a clinical-stage biotechnology company that centers on the innovation, development, and commercialization of Listeria monocytogenes (Lm) technology antigen delivery products. The company has its base of operations in the United States. ADXS stock’s product offerings include the development of ADXS-PSA, which is aimed to be used for the therapy of metastatic prostate malignant cancer and which is in the Phase 2 clinical stage.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

ADXS-503 is used for the therapy of non-small cell lung cancer and is in Phase 1/2 clinical trial; and ADXS-504 for the therapy of prostate disease.

It is likewise leading clinical investigations of Lm Technology immunotherapies in the specific areas of illnesses and diseases focused hotspot/off-the-rack neoantigen-coordinated treatments; human papilloma infection-related tumors; and prostate malignancy.

Advaxis is taking part in a presentation at ASCO Annual Meeting

ADXS stock announced that it will present information from Part B of the Phase 1 investigation of ADXS-503 in the mix with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held basically, on June 4-8, 2021. The subtleties of the presentation incorporate; the title of the show; “A stage 1 investigation of an off-the-rack, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-little cell cellular breakdown in the lungs (NSCLC) advancing on pembrolizumab as last treatment”. The meeting will be a Poster Session type.

Achieving milestone in the trial of ADXS321-164

The Company has accomplished the second achievement under its authorizing arrangement for ADXS31-164, otherwise called ADXS-HER2, to OS Therapies for assessment in the treatment of osteosarcoma in people.

This financing achievement for OS Therapies brings OST-HER2, originally ADXS-HER2, one step closer to the clinic. The OST-HER2 has a potential that ADXS stock is in to invest in and has been approved in the U.S. for the adjuvant treatment of osteosarcoma in canines, and has assumed a part in the improvement of this significant new contender for osteosarcoma patients. The group at OST will be propelling the program, expanding upon its beginning stage 1 information assessing ADXS-HER2.

This achievement phase will give Advaxisboost in the capital as ADXS accelerates across its developing ADXS-HOT neoantigen-coordinated off-the-rack clinical projects. If the company can leverage these resources while advancing in ADXS-503and ADXS-504 which is on track to enter the clinic in Q2 2021 then it will progress immensely in its pipeline achievements and progress which can translate to a positive response from investors.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Adial Pharmaceuticals Inc. (ADIL) stock plunged during pre-market trading. Here’s to know why?

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) stock gained by 9.06% at last close while the ADIL share price fell by 6.07% in the pre-market trading...

Why AbCellera Biologics Inc. (ABCL) stock faced negativity on Tuesday?

AbCellera Biologics Inc. (ABCL) shares lost 2.13% in after-hours on Tuesday, June 22, 2021, and closed the day at $21.60 per share. Earlier, ABCL's...

Biocept Inc. (BIOC) stock surged during current market trading. Why is it so?

Biocept Inc. (NASDAQ: BIOC) stock gained by 3.13% in the current market trading. Biocept creates and sells molecular diagnostic tests that offer doctors with...

Comstock Mining Inc. (LODE) stock soar during pre-market trading. What’s happening?

Comstock Mining Inc. (NASDAQ: LODE) stock gained by 1.14% at last close while the LODE stock price surged by 3.10% in the pre-market trading...

Why MediciNova Inc (MNOV) stock facing negativity since Monday’s after-hours?

MediciNova Inc. (MNOV) shares lost 5.71% in after-hours on Monday, June 21, 2021, and the plummeting continues in the pre-market session on Tuesday as...

Tiziana Life Sciences Inc. (TLSA) stock surged during pre-market. Let’s see why?

Tiziana Life Sciences Inc. (NASDAQ: TLSA) stock declined by 2.54% at last close however the TLSA stock price depicts a rise of 8.26% during...

Adial Pharmaceuticals Inc. (ADIL) stock plunged during pre-market trading. Here’s to know why?

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) stock gained by 9.06% at last close while the ADIL share price fell by 6.07% in the pre-market trading...

Histogen Inc. (HSTO) stock plunged during pre-market trading. What’s driving it low?

Histogen Inc. (NASDAQ: HSTO) stock gained by 16.16% at last close whereas the HSTO stock price declines by 2.73% in the pre-market trading. Histogen...

Related News

Orphazyme Inc. (ORPH) stock plunged during pre-market trading. Let’s see why?

Orphazyme Inc. (NASDAQ: ORPH) stock declined by 10.18% at last close whereas the ORPH stock price fell during the pre-market trading session by 58.18%....

SPI Energy Inc. (SPI) stock surged in the current market trading. Here’s the update

SPI Energy Inc. (NASDAQ: SPI) stock soars by 15.42% during the current market trading session. SPI Energy is an international renewable energy company that...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

General Employment Enterprises Inc. (JOB) stock soars during pre-market trading. Here’s to know why?

General Employment Enterprises Inc. (NASDAQ: JOB) stock gained by 1.96% at last close while the JOB stock price rises by 3.88% in the pre-market...

U.S Concrete Inc. (USCR) stock soars during pre-market trading session. What’s driving it high?

U.S Concrete Inc. (NASDAQ: USCR) stock declined by 0.66% at last close while the USCR stock price gained by 27.88% in the pre-market trading...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

7542

GIFT

Download free eBook for 

7 GROWTH  STOCKS FOR 2021

WAIT 
WE HAVE GIFT FOR YOU

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam